Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for previously treated extensive-stage small cell lung cancer
ChiCTR-OPC-17013964Phase 4Completed
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoint: progression-free survival. Started Jan 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-17013964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013964.